Gustave Roussy is the first leader cancer-research hospital in Europe and ranked among the top 5 best specialized hospitals in the world. It is a centre for high quality patient care, research and teaching. It is highly-known for the treatment of: skin cancers like melanoma, breast cancer, and lung cancer.

There are 457 beds in Gustave Roussy Cancer Campus.

During the past decade, Gustave Roussy Cancer Campus conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 3 clinical trials were completed, i.e. on average, 10.3% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 2 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gustave Roussy Cancer Campus" #1 sponsor was "Gustave Roussy, Cancer Campus, Grand Paris" with 26 trials, followed by "UNICANCER" with 9 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "The Lymphoma Academic Research Organisation" with 3 trials sponsored and "European Organisation for Research and Treatment of Cancer - EORTC" with 3 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gustave Roussy Cancer Campus" #1 collaborator was "National Cancer Institute, France" with 6 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "ETOP IBCSG Partners Foundation" with 2 trials as a collaborator, "Gilead Sciences" with 2 trials as a collaborator and "Ligue contre le cancer, France" with 2 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Gustave Roussy Cancer Campus" are "Breast Cancer" (4 trials), "Colorectal Cancer" (2 trials), "Non Small Cell Lung Cancer" (2 trials), "Prostate Cancer" (2 trials) and "Adenocarcinoma of Prostate" (1 trials). Many other conditions were trialed in "Gustave Roussy Cancer Campus" in a lesser frequency.

Most popular intervention types in "Gustave Roussy Cancer Campus" are "Drug" (28 trials), "Procedure" (10 trials), "Radiation" (7 trials), "Device" (5 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Biopsy" (4 trials), "Blood sample" (3 trials), "Cisplatin" (3 trials), "Atezolizumab" (2 trials) and "Capecitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Gustave Roussy Cancer Campus" are 38 trials for "All" genders, 8 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Gustave Roussy Cancer Campus". undefined are not yet recruiting, 12 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Gustave Roussy Cancer Campus, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Gustave Roussy Cancer Campus, 7 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 11 trials that are defined as “Not Applicable".